Is there a harder problem in science than diagnosing and treating forms of dementia? If it was a simple solution, it would have been cracked by now, said Alison Howie, chief commercial officer of neuromaging and data analysis company Ixico Ltd.
While IXICO’s goal is early, pre-symptomatic diagnosis, the company is aware of the long-term challenge of delivering that scientific and commercial breakthrough, and has been flexible in adjusting its diagnosis and therapy goals, as well as its methods, over the last 15 years of activity for the company